Technology and strategies of the immunodiagnostics market.

 The world faces tremendous disease burden through growth in epidemics such as HIV-AIDS and Hepatitis, recently, the zika disease has been circumambulating the globe as well. Most of these diseases have similar symptoms that if left undiagnosed, can lead to devastating consequences. These infectious and chronic diseases can be efficiently combated through a thorough diagnosis and different immunodiagnostic tests and analyses.

Immunodiagnostics play a vital role in understanding diseases within the human body, where the proteins expressed in the sera of a diseased person are different from those of a healthy person. These proteins therefore act as markers to determine the diseased state of a person.

Immunodiagnostics is a growing stream of applied clinical immunology where different tests are carried out to decipher the diseased state of the patient through the activity of different markers expressed through blood, serum, plasma, and other biological components. The technology utilized to analyze these biological entities needs to be designed with utmost precision, as even minute changes in the values reported as results can cause a different diagnosis, which will result in a completely different treatment, that leads to an ineffective prognosis to cure the patient. The immunodiagnostic technologies have observed an evolution in their development in recent years.
 
 There is an unaddressed need that should be met when it comes to treating infectious diseases. Logical steps need to be taken to treat pandemics, which include HIV-AIDS. According to UNAIDS, there were approximately 36.7 million people worldwide living with HIV/AIDS at the end of 2015. Of these, 1.8 million were children (<15 years old).

The global immunodiagnostics market is growing and has the fastest CAGR in terms of the Asia-Pacific region. This can be attributed to the fact that the major stakeholders of this market are setting up new community centers, health centers, and individual diagnosis laboratories through different collaboration and partnership strategies in the region. The Asia-Pacific region has tremendous potential, and is expected to drive the immunodiagnostics market in the analysis period, as different immunodiagnostic modality manufacturing companies are expanding their businesses through subsidiaries in this region.

Winning strategies

The top companies in the market have adopted product development, acquisition, collaboration and partnerships as their key development strategies in the competitive market. The information provided in this report is procured through press releases by the top companies and is limited to publicly available information and primary calls.

The pie chart shows the percentage of key strategies adopted by players in the immunodiagnostics market globally. Product development accounts for 71% share of the overall developmental strategies, as companies focused on adopting advanced and novel technologies to gain a competitive edge in the immunodiagnostics market.. The examples of product development are enlisted as follows:
•In July 2015, F. Hoffman La Roche Ltd., launched a new assay to identify Human T-lymphotropic virus I/II (HTLV-I/II) infection
•In December 2015, Bio-Rad Laboratories, Inc., received an approval from FDA for the product namely TANGO infinity system in U.S., this system automates routine blood screening testing and typing procedures
•In April 2015, Bio-Rad Laboratories, Inc. launched the S3e Cell Sorter (488/640 nm) flow cytometry equipment. This is the upgraded version to the previous series of the S3e Cell Sorters that incorporates fluorescence wavelength.

Market competitors have adopted product development as their principal strategy to enhance their services by using immunodiagnostics devices across healthcare facilities such as hospitals and clinics. Furthermore, product development is mostly targeted at serological, viral, hematological, and pathological perspectives. Increase in prevalence of diseases and technological advancements in diagnostic procedure for quick, safe, and low-cost diagnosis of diseases have increased the rate of product development, which include of product launches and product approvals by different key players.

The acquisition strategy of immunodiagnostics market covers 11% of the o